Novo Nordisk's Wegovy gets UK approval for lowering heart risks

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 23, 2024 at 11:42: AM
via Novo Nordisk's (NOVOb.CO weight-loss drug Wegovy has secured the UK regulator's approval for its use to reduce the risk of overweight and obese adults suffering serious heart problems or strokes, the agency said on Tuesday.

article source
 

<



Similar threads

cafead
Novo Nordisk bets $600M biobucks on NanoVation&#039;s ability to take genetic medicines beyond the liver
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novo Nordisk&#039;s Ozempic shortage expected to continue into Q4
Replies
0
Views
72
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Novo Nordisk&#039;s Ozempic cuts dementia risk compared with Merck&#039;s Januvia: Oxford study
Replies
0
Views
20
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biden joins Sanders&#039; campaign targeting Novo Nordisk, Eli Lilly&#039;s diabetes and obesity drug prices
Replies
0
Views
41
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
If These 3 Words Are True, Altimmune&#039;s Weight Loss Candidate Could Beat Novo Nordisk&#039;s Wegovy
Replies
0
Views
37
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote